{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:03:55Z","timestamp":1778511835140,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.canep.2022.102175","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T20:41:57Z","timestamp":1652388117000},"page":"102175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017"],"prefix":"10.1016","volume":"79","author":[{"given":"Htet Lin","family":"Htun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixiang","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"En Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling Li","family":"Foo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiat Hoe","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Yen","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5940","key":"10.1016\/j.canep.2022.102175_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.canep.2022.102175_bib2","doi-asserted-by":"crossref","first-page":"R608","DOI":"10.1016\/S0960-9822(03)00528-1","article-title":"Etten, c-Abl regulation: a tail of two lipids","volume":"13","author":"Van","year":"2003","journal-title":"Curr. Biol."},{"issue":"11","key":"10.1016\/j.canep.2022.102175_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.canep.2022.102175_bib4","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.canep.2022.102175_bib5","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2022.102175_bib7","unstructured":"National Registry of Diseases Office, Cancer Incidence and Mortality 2003\u20132012 and Selected Trends 1973\u20132012 In Singapore, 2015, pp. 1\u2013243."},{"issue":"3","key":"10.1016\/j.canep.2022.102175_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat. Med."},{"key":"10.1016\/j.canep.2022.102175_bib10","article-title":"Instructions to IBM 650 programmers in processing survival computations","author":"Ederer","year":"1959","journal-title":"Methodol. Note"},{"issue":"6","key":"10.1016\/j.canep.2022.102175_bib12","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3109\/10428194.2014.974046","article-title":"Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980\u20132009","volume":"56","author":"Penot","year":"2015","journal-title":"Leuk. Lymphom."},{"issue":"6","key":"10.1016\/j.canep.2022.102175_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.rce.2016.03.001","article-title":"Leucemia mieloide cr\u00f3nica en Espa\u00f1a: sus caracter\u00edsticas de presentaci\u00f3n han cambiado. Secci\u00f3n espa\u00f1ola del registro poblacional EUTOS","volume":"216","author":"Osorio","year":"2016","journal-title":"Rev. Cl\u00edn. Esp."},{"issue":"17","key":"10.1016\/j.canep.2022.102175_bib14","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.canep.2022.102175_bib15","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.canep.2022.102175_bib16","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1016\/j.leukres.2010.12.034","article-title":"Estimation of CML incidence: disagreement between national cancer registry and health claims data system in Taiwan","volume":"35","author":"Chang","year":"2011","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.canep.2022.102175_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/1472-6963-12-359","article-title":"Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis","volume":"12","author":"Chang","year":"2012","journal-title":"BMC Health Serv. Res."},{"issue":"2","key":"10.1016\/j.canep.2022.102175_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ejh.12695","article-title":"Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012","volume":"97","author":"Thielen","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.canep.2022.102175_bib19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41598-021-03734-6","article-title":"Incidence of myeloid neoplasms in Spain (2002\u20132013): a population-based study of the Spanish network of cancer registries","volume":"12","author":"Solans","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canep.2022.102175_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: occurrence, progression and survival in the UK\u2019s population-based haematological malignancy research network 2004\u201315","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.canep.2022.102175_bib21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1186\/s13104-018-3890-8","article-title":"Incidence of chronic myeloid leukemia in Calgary, Alberta, Canada","volume":"11","author":"Nguyen","year":"2018","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.canep.2022.102175_bib22","doi-asserted-by":"crossref","unstructured":"A. Nennecke A. Wienecke K. Kraywinkel Inzidenz und \u00dcberleben bei Leuk\u00e4mien in Deutschland nach aktuellen standardisierten Kategorien Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 57 1 2014 93 102.","DOI":"10.1007\/s00103-013-1869-0"},{"issue":"1","key":"10.1016\/j.canep.2022.102175_bib23","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-016-2238-9","article-title":"Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000\u20132013","volume":"16","author":"Beinortas","year":"2016","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.canep.2022.102175_bib24","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.canep.2022.102175_bib25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5045\/br.2015.50.4.204","article-title":"Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012","volume":"50","author":"Park","year":"2015","journal-title":"Blood Res."},{"issue":"7","key":"10.1016\/j.canep.2022.102175_bib26","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk. Lymph."},{"issue":"1","key":"10.1016\/j.canep.2022.102175_bib27","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1038\/s41598-019-48445-1","article-title":"An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States","volume":"9","author":"Hao","year":"2019","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.canep.2022.102175_bib28","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/cncr.11316","article-title":"Trends in leukemia incidence and survival in the United States (1973\u20131998)","volume":"97","author":"Xie","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.canep.2022.102175_bib29","doi-asserted-by":"crossref","DOI":"10.3325\/cmj.2012.53.115","article-title":"Incidence and mortality trends of leukemia and lymphoma in Croatia, 1988-2009","volume":"53","author":"Novak","year":"2012","journal-title":"Croat. Med. J."},{"issue":"11","key":"10.1016\/j.canep.2022.102175_bib30","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.leukres.2010.03.033","article-title":"Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era","volume":"34","author":"Kim","year":"2010","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.canep.2022.102175_bib31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jiph.2019.12.006","article-title":"Evaluation and characterisation of Chronic myeloid leukemia and various treatments in Saudi Arabia: a retrospective study","volume":"13","author":"Algahtani","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.canep.2022.102175_bib32","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3332\/ecancer.2020.1089","article-title":"Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment","volume":"14","author":"Henke","year":"2020","journal-title":"Ecancermedicalscience"},{"issue":"18","key":"10.1016\/j.canep.2022.102175_bib33","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2022.102175_bib34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ejh.12788","article-title":"Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway","volume":"98","author":"Roaldsnes","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"10","key":"10.1016\/j.canep.2022.102175_bib35","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3346\/jkms.2016.31.10.1579","article-title":"Incidence, survival and prevalence statistics of classical myeloproliferative neoplasm in Korea","volume":"31","author":"Lim","year":"2016","journal-title":"J. Korean Med. Sci."},{"issue":"1","key":"10.1016\/j.canep.2022.102175_bib36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13104-019-4321-1","article-title":"Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada","volume":"12","author":"Heppner","year":"2019","journal-title":"BMC Res. Notes"},{"issue":"3","key":"10.1016\/j.canep.2022.102175_bib37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u201312","volume":"174","author":"Srour","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.canep.2022.102175_bib38","doi-asserted-by":"crossref","first-page":"E107","DOI":"10.1002\/ajh.25407","article-title":"Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014","volume":"94","author":"Baade","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.canep.2022.102175_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000595","article-title":"Survival in primary myelofibrosis: a population-based analysis in the Netherlands","volume":"5","author":"Slot","year":"2021","journal-title":"HemaSphere"},{"issue":"4","key":"10.1016\/j.canep.2022.102175_bib40","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/joim.13019","article-title":"Incidence of myeloproliferative neoplasms \u2013 trends by subgroup and age in a population-based study in Sweden","volume":"287","author":"Hultcrantz","year":"2020","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.canep.2022.102175_bib41","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk. Lymphoma."},{"issue":"2","key":"10.1016\/j.canep.2022.102175_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"issue":"22","key":"10.1016\/j.canep.2022.102175_bib43","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1002\/cncr.32417","article-title":"Identification of significant geographic clustering of polycythemia vera cases in Montreal, Canada","volume":"125","author":"Le","year":"2019","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.canep.2022.102175_bib44","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00432-015-1983-5","article-title":"Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973\u20132011","volume":"141","author":"Deadmond","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.canep.2022.102175_bib45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? a systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"24","key":"10.1016\/j.canep.2022.102175_bib46","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canep.2022.102175_bib47","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.canep.2022.102175_bib48","doi-asserted-by":"crossref","DOI":"10.1055\/s-2006-939430","article-title":"Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia","volume":"32","author":"Johansson","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"issue":"6","key":"10.1016\/j.canep.2022.102175_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ejh.12873","article-title":"Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: real-world data from the Swedish MPN registry","volume":"98","author":"Abdulkarim","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.canep.2022.102175_bib50","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canep.2022.102175_bib51","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1055-9965.EPI-11-1087","article-title":"Underreporting of myeloid malignancies by United States cancer registries","volume":"21","author":"Craig","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prevent."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782122000807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782122000807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:31:02Z","timestamp":1761802262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782122000807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":48,"alternative-id":["S1877782122000807"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2022.102175","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2022.102175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102175"}}